SRRK Company Profile and Key Details

Q: Who are the executives of SRRK?

Mr. Edward H. Myles M.B.A., MBAChief Financial Officer, Chief Operating Officer & TreasurerMr. Edward H. Myles MBAChief Financial Officer, Chief Operating Officer & TreasurerMs. Junlin Ho J.D.Gen. Counsel & Corporation Sec.Ms. Catherine HuVice President of Investor Relations & Corporation CommunicationsMs. Caryn ParlavecchioChief HR OfficerMs. Erin MooreSenior Vice President of Fin.Mr. Ryan IarrobinoSenior Vice President of Clinical Devel. & OperationsDr. Jing L. Marantz M.B.A., M.D., Ph.D.Chief Medical OfficerMs. Tracey M. Sacco M.B.A.Chief Commercial OfficerDr. Jay T. Backstrom M.D., M.P.H.Pres, Chief Executive Officer & DirectorMs. Lisa Amaya PriceSenior Vice President & Chief HR Officer

NASDAQ : SRRK

Scholar Rock Holding

$46.07

1.33+2.97%

Open: 3:54 PM

57.53

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Scholar Rock Holding Corporation (SRRK) stock surged +2.97%, trading at $46.07 on NASDAQ, up from the previous close of $44.74. The stock opened at $44.93, fluctuating between $44.52 and $46.35 in the recent session.

Stock Snapshot

44.74

Prev. Close

4.7B

Market Cap

44.52

Day Low

-14.63

P/E Ratio

-3.15

EPS (TTM)

-1.91

Cash Flow per Share

44.93

Open

102.01M

Number of Shares

46.35

Day High

83.57%

Free Float in %

2.96

Book Value

897.43K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 20, 2026	44.10	44.87	43.25	44.74	1.06M
Jan 16, 2026	46.11	46.22	44.02	44.97	867.73K
Jan 15, 2026	45.44	46.75	43.95	46.53	988.38K
Jan 14, 2026	43.57	46.74	43.19	45.58	1.44M
Jan 13, 2026	42.83	44.22	42.10	43.75	1.85M
Jan 12, 2026	42.07	43.66	40.63	43.56	1.15M
Jan 09, 2026	41.74	43.62	41.73	42.18	943.53K
Jan 08, 2026	43.63	43.85	41.00	41.67	1.2M
Jan 07, 2026	42.67	44.50	41.32	44.23	1.31M
Jan 06, 2026	42.57	43.06	41.19	41.31	755.44K
Jan 05, 2026	42.33	43.19	41.20	42.76	1.2M
Jan 02, 2026	43.99	44.19	41.76	42.80	817.99K
Dec 31, 2025	43.55	44.40	43.33	44.05	599.9K
Dec 30, 2025	45.18	45.21	43.55	43.62	766.87K
Dec 29, 2025	45.76	46.14	44.74	45.19	651.14K
Dec 26, 2025	45.47	46.06	45.13	45.67	510.78K
Dec 24, 2025	45.76	46.30	45.13	45.86	433.65K
Dec 23, 2025	45.00	46.38	45.00	45.89	1.12M
Dec 22, 2025	43.65	45.23	43.28	45.20	638.63K
Dec 19, 2025	43.13	44.44	43.13	43.90	1.43M

Contact Details

Cambridge, MA 02142

United States

https://scholarrock.com 857 259 3860

About Company

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Stock Peers

ARGX

9.63+1.20%

argenx SE$809.64 REGN

0.74+0.10%

Regeneron Pharmaceuticals, Inc.$733.78 MDGL

3.27+0.65%

Madrigal Pharmaceuticals, Inc.$504.95 UTHR

3.14+0.68%

United Therapeutics Corporation$468.07 VRTX

0.72+0.16%

Vertex Pharmaceuticals Incorporated$442.08 ALNY

-3.74-1.04%

Alnylam Pharmaceuticals, Inc.$355.53 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

6.83+2.15%

Praxis Precision Medicines, Inc.$324.08 KRYS

-10.23-3.59%

Krystal Biotech, Inc.$274.81 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Scholar Rock Holding Corporation (NASDAQ:SRRK) closed at $46.07 USD, gaining $1.33 (2.97%) from the previous close of $44.74. The stock is currently within 5% of its 52-week high $22.71 and $48.28. With a market capitalization of about $4.70 billion, Scholar Rock Holding Corporation is classified as a mid-cap and shows lower-than-market volatility (beta ~0.64). Key stats such as the average daily volume over the past year has been around 1.59 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Scholar Rock Holding Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO David L. Hallal, the company employs approximately 128 people and listed since May 25, 2018. Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 1.28%, SMA50 7.23%, SMA200 26.99%). The stock’s 14-day RSI is 54.2 (neutral), while the ATR of 2.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.33% below its high and over 97.01% above its low. Average 10-day trading volume of 1.23 million shares is below the 3-month average of 1.59 million, indicating normal recent market interest.

Valuation Metrics

Scholar Rock Holding Corporation trades at a P/E ratio of -14.22, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 20.51 reflecting a rich premium to book value. The P/FCF stands at -16.41, also below market averages. Compared to sector medians, Scholar Rock Holding Corporation P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Scholar Rock Holding Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.13. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Scholar Rock Holding Corporation generated EPS of -$3.25 over the past year. Five-year average earnings growth is -5.9%. Wall Street analysts project EPS growth of 11.14% annually over the next five years. The latest quarter delivered EPS of -$0.90. The next quarter is forecast at -$0.90. Next year's EPS is expected at $3.14. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $42.00. The high target offers 34.11% upside. The low target suggests -6.12% downside. The mean target is $48.36. This offers 8.09% upside. Scholar Rock Holding Corporation earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 14, 2025, missed forecasts by 7.62%. The prior quarter beat by 48.48%. Over the last six quarters, Apple has recorded several small beats. These include -0.93% in August 08, 2024.

Shareholding & Insider Activity

Scholar Rock Holding Corporation has 96.13 million shares outstanding. The public float is 80.45 million shares, elevated short interest at 28.19% of float. This equals 15.47 million shares. The short ratio is 9.54 days. Institutional investors hold 123.77% of the float. Insiders own 3.76%. Invus Public Equities, L.P. holds 9.25 million shares, Invus Public Equities Advisors, LLC has 8.85 million shares and Samsara BioCapital GP, LLC has 6.79 million shares. Over the past six months, insider transactions show net selling. They sold 270.03 thousand shares across 11 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Scholar Rock Holding has not generated any revenue. Returns are negative, with ROA at -53.30% and ROE at -73.61%.
On valuation metrics, Scholar Rock Holding trades at a P/E of -14.22, P/S of 0.00 and P/B of 20.51. The current ratio is 6.30 and quick ratio is 6.30. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1516.72 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.45, supported by a cash flow-to-debt ratio of -2.49.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Scholar Rock Holding posted revenue of $0.00, down slightly from $33.19M in the prior quarter. Gross profit was - $2.84M (margin 0.00%). Operating income was - $171.30M (margin 0.0%). Net income was- $165.79M (EPS - $1.99).
The company ended the quarter with $279.94M in cash and short-term investments, a total debt of $61.82M, and net debt of - $40.04M. Total assets were $311.04M, with equity of $225.22M. Financials further reflected weakness, with operating cash flow of - $145.23M, free cash flow of - $145.30M, and capital expenditures of - $71.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Scholar Rock Holding Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.98%, with price expected at $44.30 by February 03, 2026, within a range of $42.65 to $45.87 3-Month Outlook: Projected fall of -35.27%, reaching $28.96 by April 16, 2026, with a range of $27.79 to $30.06. 1-Year Outlook: Projected gain of 26.2%, with price at $56.46 by January 15, 2027, within a range of $53.91 to $59.50.

Key Takeaways

Scholar Rock Holding Corporation (NASDAQ:SRRK) shares are flat 1.57% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Scholar Rock Holding Corporation trading at a premium to the broader market with a P/E of -14.22. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $40.20, suggesting -10.15% downside. Our AI forecast model points to short-term weakness (-0.98% over two weeks), a medium-term fall (-35.27% over three months), and a longer-term gain (26.2% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Scholar Rock Holding Corporation (SRRK) stock price?

Scholar Rock Holding Corporation (NASDAQ: SRRK) stock price is $46.07 in the last trading session. During the trading session, SRRK stock reached the peak price of $46.35 while $44.52 was the lowest point it dropped to. The percentage change in SRRK stock occurred in the recent session was 2.97% while the dollar amount for the price change in SRRK stock was $1.33.

SRRK's industry and sector of operation?

The NASDAQ listed SRRK is part of Biotechnology industry that operates in the broader Healthcare sector. Scholar Rock Holding Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SRRK?

Mr. Edward H. Myles M.B.A., MBA
Chief Financial Officer, Chief Operating Officer & Treasurer
Mr. Edward H. Myles MBA
Chief Financial Officer, Chief Operating Officer & Treasurer
Ms. Junlin Ho J.D.
Gen. Counsel & Corporation Sec.
Ms. Catherine Hu
Vice President of Investor Relations & Corporation Communications
Ms. Caryn Parlavecchio
Chief HR Officer
Ms. Erin Moore
Senior Vice President of Fin.
Mr. Ryan Iarrobino
Senior Vice President of Clinical Devel. & Operations
Dr. Jing L. Marantz M.B.A., M.D., Ph.D.
Chief Medical Officer
Ms. Tracey M. Sacco M.B.A.
Chief Commercial Officer
Dr. Jay T. Backstrom M.D., M.P.H.
Pres, Chief Executive Officer & Director
Ms. Lisa Amaya Price
Senior Vice President & Chief HR Officer

How SRRK did perform over past 52-week?

SRRK's closing price is 97.01% higher than its 52-week low of $22.71 where as its distance from 52-week high of $48.28 is -7.33%.

How many employees does SRRK have?

Number of SRRK employees currently stands at 128.

Link for SRRK official website?

Official Website of SRRK is: https://scholarrock.com

How do I contact SRRK?

SRRK could be contacted at phone 857 259 3860 and can also be accessed through its website. SRRK operates from 301 Binney Street, Cambridge, MA 02142, United States.

How many shares of SRRK are traded daily?

SRRK stock volume for the day was 897.43K shares. The average number of SRRK shares traded daily for last 3 months was 1.59M.

What is the market cap of SRRK currently?

The market value of SRRK currently stands at $4.70B with its latest stock price at $46.07 and 102.01M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	128
Beta	0.64
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

SRRK Company Profile and Key Details

Scholar Rock Holding

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook